Sort
51,593 grants matching “hepatitis”
Role of the innate immune defenses in viral infections
$829,217Barbara Rehermann · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2021 · DK
DEVELOPING RAPID ASSAYS FOR HEPATITIS VIRUS IN BLOOD SUPPLY SUITABLE FOR USE IN FIELD ENVIRONMENT
$829,175The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. · · FY2009 · Department of the Army
Development of an engineered CCL20 protein as a lead therapeutic molecule for psoriasis
$829,097Brian F Volkman · Xlock Biosciences, Llc · R44 · FY2021 · AR
Treatment for alcoholic liver disease
$829,090Bert J. W. M. Oehlen · Angion Biomedica Corporation · R44 · FY2011 · AA
YAP signaling in the pathogenesis of NAFLD in people living with HIV
$829,042Raymond T Chung · Massachusetts General Hospital · R01 · FY2023 · DK
Mechanisms of Drug Disposition During Pregnancy
$828,926Jashvant D Unadkat · University Of Washington · P01 · FY2013 · DA
The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)
$828,733Charles W. Flexner · Johns Hopkins University · R24 · FY2023 · AI
Childhood Liver Disease Research Network Data Coordinating Center
$828,587John C Magee · University Of Michigan At Ann Arbor · U01 · FY2015 · DK
Liver Cancer Disparities in Alaska Native and American Indian People
$828,416George Ioannou · University Of Washington · P20 · FY2023 · CA
An Interdisciplinary Approach to HIV and Other Infectious Diseases of Drug Users
$828,153Sherry Deren · New York University · P30 · FY2011 · DA
Biofilm Epidemiology and Mechanisms in Colon Cancer
$828,069Cynthia L Sears · Johns Hopkins University · R01 · FY2020 · CA
Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine
$828,035Sebastian Seiguer · Emocha Mobile Health, Inc. · R44 · FY2019 · DA
Nonalcoholic Steatohepatitis: Natural History, Pathogenesis and Therapy
$827,898Yaron Rotman · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2014 · DK
Disordered Cellular Cholesterol Movement, Cell Death, and Multisystem Disease
$827,892Stephen Dean Turley · Ut Southwestern Medical Center · R01 · FY2013 · HL
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies
$827,529Inga Peter · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · HG
Mid Southern Primary Care Networks Node
$827,206Li-Tzy T Wu · Duke University · UG1 · FY2015 · DA
Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity
$827,199Wen Xie · University Of Pittsburgh At Pittsburgh · R35 · FY2024 · ES
Immunologic and Metabolic Profiles of T cells that control diverse HCV infections
$827,166Andrea L Cox · Johns Hopkins University · U19 · FY2024 · AI
NATURAL HSITORY OF HTLV 1 AND HCV INFECTIONS
$827,092Harvard University (Sch Of Public Hlth) · R01 · FY2000 · CA
A preclinical multi-modal system for dynamic noninvasive assessment of liver disease
$826,935Tomasz Joseph Czernuszewicz · Sonovol, Inc. · R44 · FY2019 · DK
Long Acting Beta Interferon for Treating Multiple Sclerosis - Phase II Continuing
$826,535George Norbert Cox · Bolder Biotechnology, Inc. · R44 · FY2008 · NS
The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination
$826,337David L Thomas · Johns Hopkins University · R01 · FY2020 · DA
HIV Risk and Neighborhood Networks of New IDUs
$826,290National Development &Res Institutes · R01 · FY2004 · DA
Physiologic Consequence of Genetic Variation
$825,938Richard M Watanabe · University Of Southern California · R01 · FY2015 · DK
AlcHepNet DCC UMMS
$825,889Bruce A Barton · Univ Of Massachusetts Med Sch Worcester · U24 · FY2022 · AA